By Research Area
Hot products 
-
Mouse Anti-CD24 Recombinant Antibody (2Q1282) (CBMAB-C1624-CN)
-
Mouse Anti-dsRNA Recombinant Antibody (2) (CBMAB-D1807-YC)
-
Rabbit Anti-ADRA1A Recombinant Antibody (V2-12532) (CBMAB-1022-CN)
-
Mouse Anti-BAD (Phospho-Ser136) Recombinant Antibody (CBYY-0138) (CBMAB-0139-YY)
-
Mouse Anti-BBS2 Recombinant Antibody (CBYY-0253) (CBMAB-0254-YY)
-
Mouse Anti-GFAP Recombinant Antibody (20) (CBMAB-G2914-LY)
-
Mouse Anti-CCND2 Recombinant Antibody (DCS-3) (CBMAB-G1318-LY)
-
Mouse Anti-ALB Recombinant Antibody (V2-180650) (CBMAB-A2186-YC)
-
Mouse Anti-HTLV-1 gp46 Recombinant Antibody (CBMW-H1006) (CBMAB-V208-1154-FY)
-
Mouse Anti-EPO Recombinant Antibody (CBFYR0196) (CBMAB-R0196-FY)
-
Mouse Anti-APOE Recombinant Antibody (A1) (CBMAB-0078CQ)
-
Human Anti-SARS-CoV-2 Spike Recombinant Antibody (CBC05) (CBMAB-CR005LY)
-
Mouse Anti-AFDN Recombinant Antibody (V2-58751) (CBMAB-L0408-YJ)
-
Mouse Anti-C4B Recombinant Antibody (CBYY-C2996) (CBMAB-C4439-YY)
-
Mouse Anti-CD1C Recombinant Antibody (L161) (CBMAB-C2173-CQ)
-
Mouse Anti-ESR1 Recombinant Antibody (Y31) (CBMAB-1208-YC)
-
Mouse Anti-ARG1 Recombinant Antibody (CBYCL-103) (CBMAB-L0004-YC)
-
Mouse Anti-ALB Recombinant Antibody (V2-363290) (CBMAB-S0173-CQ)
-
Mouse Anti-ENPP1 Recombinant Antibody (CBFYE-0159) (CBMAB-E0375-FY)
-
Rabbit Anti-Acetyl-Histone H3 (Lys36) Recombinant Antibody (V2-623395) (CBMAB-CP0994-LY)
Melanoma Research
Melanoma has long been the paradigm for the success of cancer immunotherapy, fundamentally transformed by the clinical introduction of PD-1 and CTLA-4 blockade. While these therapies have extended survival for many metastatic patients, the complexity of melanoma biology demands a dual focus: absolute precision in histopathological diagnosis to guide initial management, and the identification of predictive biomarkers to optimize immunotherapy. The modern clinical workflow integrates robust lineage-specific markers with immune checkpoint analysis to stratify patients and differentiate melanoma from undifferentiated carcinomas or sarcomas, particularly in metastatic settings where morphological features can be ambiguous.
Research Hotspots in Melanoma
The PD-1/PD-L1 axis remains the cornerstone of melanoma management. However, the variable response rates underscore the need to understand resistance mechanisms and tumor heterogeneity. Research is increasingly reliant on the "Diagnostic Triad" of S100, MART-1 (Melan-A), and SOX10 to map tumor burden and origin.
S100 remains the most sensitive pan-melanoma marker, indispensable for initial screening of suspected lesions. However, its lack of specificity has elevated the importance of SOX10 and MART-1. SOX10, a nuclear transcription factor, has emerged as the gold standard for sensitivity and specificity, particularly in detecting desmoplastic melanoma and micrometastases in sentinel lymph nodes that traditional markers might miss. MART-1, recognized by T-cells, complements this by providing robust cytoplasmic staining for confirming melanocytic lineage. The integration of these diagnostic heavyweights with PD-L1 expression profiling enables a comprehensive "immune-pathological" map, allowing researchers to correlate tumor lineage characteristics with immune evasion phenotypes.
Creative Biolabs Antibody Solutions
Creative Biolabs is dedicated to supporting the complete spectrum of melanoma research, from diagnostic pathology to immuno-oncology. We offer a premier collection of antibodies featuring the essential diagnostic panel: Anti-S100, Anti-SOX10, and Anti-MART-1. Complementing these are our gold-standard reagents for immunotherapy research, including validated antibodies for PD-1 and PD-L1 optimized for immunohistochemistry and flow cytometry. By utilizing Creative Biolabs' verified reagents, scientists can ensure accurate tumor identification while simultaneously profiling the immune landscape, facilitating a seamless transition from benchside diagnosis to therapeutic discovery.
Loading...
Compare
